Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NAVX-010 - A Phase I, Double-Blind, Placebo-Controlled, Single-Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects

NCT03655522 is registered in ClinicalTrials.gov with Algenis SpA as lead sponsor.

NCT NCT03655522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03655522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NAVX-010 - A Phase I, Double-Blind, Placebo-Controlled, Single-Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects
Lead sponsor
Algenis SpA
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2015
Completion date
September 2, 2015
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

safety